Women's Health

What Supplements Affect AMH Levels in Women?

AMH (anti-Müllerian hormone) is one of the most reliable markers of ovarian reserve, yet most women don't know their number until fertility becomes a concern. Research suggests that oxidative stress, mitochondrial dysfunction, and nutrient deficiencies can accelerate the decline of AMH — and that targeted supplementation may slow that process for some women.

Jared Murray ·Co-Founder & Head of Health Research, Ones · ·10 min read
AMHovarian reservewomen's fertility supplementsCoQ10 fertilityalpha lipoic acid womenresveratrol women
What Supplements Affect AMH Levels in Women?

What Supplements Affect AMH Levels in Women?

Some supplements may modestly support AMH levels, primarily by reducing ovarian oxidative stress and improving mitochondrial function in granulosa cells. The evidence is strongest for antioxidants like alpha-lipoic acid, DHEA, CoQ10, and emerging compounds like resveratrol and NMN. The main caveat: none of these reverse significant ovarian aging, and women with severely low AMH (<0.3 ng/mL) should not rely on supplements alone — these work best as preventive or adjunctive tools.

Why AMH Matters and What Can Lower It

Anti-Müllerian hormone is secreted by the granulosa cells surrounding developing follicles in the ovaries. Clinicians use it as the gold-standard indirect measure of ovarian reserve — how many eggs remain. Unlike FSH or estradiol, AMH stays relatively stable across the menstrual cycle, making it a reliable single-draw marker.

Several modifiable factors can suppress AMH below what your biological age would predict:

  • Chronic oxidative stress damages follicular DNA and accelerates follicle death
  • Mitochondrial dysfunction impairs the energy supply that granulosa cells need to survive
  • Micronutrient deficiencies (vitamin D, zinc, CoQ10) reduce cellular resilience
  • Thyroid dysregulation — subclinical hypothyroidism is associated with lower AMH in some cross-sectional data (Weghofer et al., Fertility and Sterility 2010; PMID: 19523620)
  • Insulin resistance and PCOS create a paradox: AMH is often elevated in PCOS but follicle quality suffers
  • Smoking and environmental toxins (BPA, phthalates) are among the most damaging environmental suppressors

Understanding what's driving your specific AMH trajectory matters enormously. A woman with low AMH secondary to vitamin D deficiency and poor mitochondrial health responds very differently to supplementation than one whose reserve is genetically limited. Tracking biomarkers like vitamin D levels or cortisol alongside AMH gives you a fuller picture.

CoQ10 and Mitochondrial Support for Ovarian Reserve

CoQ10 (coenzyme Q10) is the most studied supplement in the context of ovarian aging. Granulosa cells are metabolically demanding — they rely heavily on mitochondrial ATP production to survive and support oocyte development. CoQ10 sits at the heart of the electron transport chain and also acts as a lipid-soluble antioxidant inside mitochondrial membranes.

A landmark randomized controlled trial by Bentov et al. (Molecular Human Reproduction 2010; PMID: 20385590) demonstrated that CoQ10 supplementation improved mitochondrial function in oocytes of older women (38–46 years) undergoing IVF. A subsequent trial published in Fertility and Sterility found that women supplementing 600 mg/day of CoQ10 for 60 days before IVF retrieval had significantly more mature oocytes and higher fertilization rates compared to placebo (Xu et al., Fertility and Sterility 2018; PMID: 29197618).

While these trials measured oocyte quality and IVF outcomes rather than AMH directly, they establish the mechanistic pathway: better mitochondrial health → less follicular atresia → potentially preserved AMH over time. The clinical dose used in these trials ranges from 400–600 mg/day, with ubiquinol (the reduced, more bioavailable form) preferred in women over 35.

Alpha Lipoic Acid for Women: Antioxidant Protection in the Ovary

Alpha-lipoic acid (ALA) is a universal antioxidant — it's both water- and fat-soluble, regenerates vitamins C and E, and boosts glutathione synthesis inside cells. In the context of ovarian biology, ALA's ability to neutralize reactive oxygen species (ROS) in follicular fluid is particularly relevant.

Follicular fluid ROS levels are strongly inversely correlated with oocyte quality and clinical pregnancy rates (Pasqualotto et al., Journal of Assisted Reproduction and Genetics 2004; PMID: 15106562). ALA directly scavenges ROS in follicular fluid and upregulates the cell's own antioxidant defenses via the Nrf2 pathway.

A 2019 study in women with diminished ovarian reserve found that combined ALA (400 mg/day) plus folic acid supplementation was associated with a small but statistically significant increase in antral follicle count (AFC) over 3 months compared to folic acid alone (Strojny et al., Ginekologia Polska 2019; PMID: 31680243). AFC and AMH track closely as measures of ovarian reserve, so this is a meaningful surrogate endpoint.

ALA also improves insulin sensitivity, which matters for women whose AMH is suppressed in the context of PCOS or metabolic dysfunction. At doses of 300–600 mg/day, ALA has demonstrated meaningful improvements in insulin-stimulated glucose disposal in women with PCOS (Genazzani et al., Gynecological Endocrinology 2008; PMID: 19031218).

For women with elevated fasting insulin alongside low AMH, ALA represents one of the more mechanistically rational choices in the supplement toolkit.

Resveratrol for Women: NAD+ Precursor and SIRT1 Activator

Resveratrol is a polyphenol found in red grape skins that gained scientific attention primarily as a SIRT1 activator — sirtuins are NAD+-dependent enzymes that regulate cellular stress responses, mitochondrial biogenesis, and DNA repair. In the ovary, SIRT1 and SIRT3 activity declines with age and is associated with reduced oocyte quality.

A mouse study published in Human Reproduction demonstrated that resveratrol supplementation preserved ovarian reserve, reduced follicular apoptosis, and maintained AMH-positive follicle counts in aging mice (Liu et al., Human Reproduction 2013; PMID: 23329726). Human data is more limited, but a clinical pilot in women with PCOS found that resveratrol (1500 mg/day for 3 months) significantly lowered testosterone and LH levels, indicating meaningful hormonal modulation (Banaszewska et al., Journal of Clinical Endocrinology & Metabolism 2016; PMID: 26678483).

The AMH-specific human evidence remains preliminary. What resveratrol does have is a credible mechanism: by boosting SIRT1 activity and supporting mitochondrial biogenesis via PGC-1α, it targets the same upstream pathways that CoQ10 addresses from the energy-production side. Many reproductive endocrinologists consider them complementary rather than redundant.

At standard research doses of 500–1500 mg/day, resveratrol is generally well tolerated. Because it weakly inhibits CYP enzymes, women on medications should check for interactions before adding high-dose resveratrol.

NMN for Women and NAD+ Biology in Ovarian Aging

Nicotinamide mononucleotide (NMN) is a direct precursor to NAD+ — the coenzyme that powers sirtuins, PARP DNA repair enzymes, and mitochondrial energy production. NAD+ levels decline substantially with age in most tissues, including ovarian tissue.

The connection between NAD+ and female fertility was highlighted in a groundbreaking study by Bertoldo et al. (Cell Reports 2020; PMID: 32640232), which showed that NMN supplementation in aged female mice restored ovarian NAD+ levels, improved oocyte quality, increased ovulation rates, and rescued key meiotic spindle defects that accumulate with aging. AMH-positive follicle counts were also preserved in the NMN-treated group versus controls.

This is some of the most mechanistically compelling preclinical evidence in reproductive aging biology. The question for clinical translation is dose and form. Human NMN pharmacokinetic studies show that oral NMN is absorbed and raises blood NAD+ levels in a dose-dependent manner (Yoshino et al., Cell Metabolism 2021; PMID: 34727564), with doses of 250–500 mg/day used in clinical trials showing metabolic and energy benefits.

No completed RCT has yet measured AMH as a primary endpoint in NMN-supplemented women. What exists is strong preclinical mechanistic data, early human PK validation, and a biologically coherent pathway. For women interested in ovarian longevity — particularly those in their late 30s who are not yet symptomatic — NMN represents a rational, evidence-informed option, with appropriate expectation-setting about the state of the evidence.

NAD for Women: The Broader Ecosystem

NMN is one route to raising NAD+, but the broader NAD+ ecosystem includes nicotinamide riboside (NR), niacin, and lifestyle factors like exercise and caloric restriction. For the purposes of ovarian reserve, the mechanism matters more than the specific precursor: restoring NAD+ availability in granulosa cells supports sirtuin activity, reduces ROS, and improves mitochondrial efficiency — all of which converge on slower follicular attrition.

Iron status is an underappreciated variable in this picture. Iron is essential for mitochondrial function, and women with low ferritin frequently show compounding fatigue and reduced cellular energy that may worsen ovarian cell resilience. If your AMH is low alongside low hemoglobin or ferritin, addressing iron levels is a sensible parallel priority.

Zinc also plays a role in oocyte maturation and granulosa cell function. Women with inadequate zinc show impaired folliculogenesis in animal models, and clinical data suggest that zinc supplementation can modulate reproductive hormone profiles. Optimizing these foundational micronutrients creates a better cellular environment for the more targeted interventions like NMN or CoQ10 to work in.

DHEA: The Most Studied Supplement for Diminished Ovarian Reserve

No discussion of supplements and AMH would be complete without DHEA. Dehydroepiandrosterone is the adrenal precursor to both testosterone and estrogen, and testosterone receptors are expressed on granulosa cells, where local androgen signaling supports follicle survival.

Over a dozen small trials and retrospective studies have examined DHEA supplementation (25–75 mg/day) in women with diminished ovarian reserve undergoing IVF. A systematic review and meta-analysis published in Reproductive Biology and Endocrinology (Nagels et al. 2015; PMID: 25880814) found statistically significant improvements in AMH and antral follicle count in DHEA-supplemented women, alongside trends toward higher live birth rates — though effect sizes were modest and study quality was variable.

DHEA is notably different from the other compounds on this list because it has direct hormonal activity. Women with PCOS, hormone-sensitive conditions, or existing androgen excess should not use DHEA without medical supervision. For women with clearly diminished ovarian reserve who have confirmed low DHEA-S on blood work, however, it remains the supplement with the most clinical trial data specific to AMH.

What This Means for Your Formula

Amh is a downstream readout of ovarian cell health — it's essentially a measure of how many metabolically functional granulosa cells you have. That framing makes it obvious why no single supplement is a magic bullet: ovarian reserve decline is multifactorial, and meaningful support requires addressing mitochondrial function, oxidative stress, and micronutrient status simultaneously.

Ones builds personalized formulas based on your blood results, wearable data, and health history. For women whose lab work reveals patterns relevant to ovarian reserve — such as low vitamin D, elevated inflammatory markers, or signs of mitochondrial insufficiency — a Ones formula might include:

  • CoQ10/Ubiquinol at 200 mg as a foundation for mitochondrial electron transport chain support — this is a clinically recognized dose for cellular energy production, though reproductive-specific trials have used 400–600 mg in cycling women, which Ones can accommodate within the custom capsule budget
  • Zinc at clinically validated doses to support granulosa cell function and folliculogenesis, alongside other foundational micronutrients flagged by your bloodwork
  • Ones' Adrenal Support blend for women whose cortisol and DHEA-S patterns suggest adrenal involvement in reproductive hormone dysregulation — supporting adrenal output is often a prerequisite for downstream hormone optimization

Because AMH isn't a supplement-specific biomarker in the conventional sense, Ones' AI practitioner looks at the constellation of findings — not just one number — to determine which ingredients have the highest probability of benefit for your specific profile. The 6- or 9-capsule daily plan is calibrated automatically based on what your data shows, not on what you select from a menu.

Key Takeaways

  • AMH reflects ovarian granulosa cell health — supplements that reduce oxidative stress and support mitochondrial function in follicles are the most mechanistically justified choices
  • CoQ10 (400–600 mg/day) has the strongest human trial data for improving oocyte quality and is the most established supplement in the ovarian reserve space
  • Alpha-lipoic acid (300–600 mg/day) offers dual benefits: antioxidant protection in follicular fluid and improved insulin sensitivity, particularly relevant for women with PCOS or metabolic dysfunction
  • Resveratrol and NMN target NAD+/sirtuin biology with compelling preclinical and early human evidence — they're rational additions for women focused on ovarian longevity, with the caveat that AMH-specific human RCT data is still emerging
  • DHEA (25–75 mg/day) has the most AMH-specific clinical trial data but carries hormonal activity and requires medical supervision — not a self-prescribe supplement
  • Foundational micronutrients (vitamin D, zinc, iron) create the cellular environment that makes targeted interventions effective — addressing deficiencies here is a prerequisite, not an afterthought
  • Always consult a reproductive endocrinologist or healthcare provider before using supplements specifically to influence fertility outcomes

Written by Jared Murray, Co-Founder & Head of Health Research, Ones.

Jared is the co-founder and head of health research at Ones, with 25 years applying nutrition science, biomarker interpretation, and clinical supplementation research to individual health programs. He leads the editorial process for the Ones Health Library, where lab data, wearable biometrics, and peer-reviewed clinical research are translated into evidence-based, personalized supplement guidance.

Disclosure: Ones formulates and sells personalized supplements that may include ingredients discussed in this article. We have a financial interest in the products mentioned. Recommendations are based on published research and our editorial standards, not sales targets.

This article is educational content, not medical advice. Consult a healthcare provider before changing your supplement regimen.

Further reading

Related reading